OmniAb, Inc. (OABI) stock: key figures, P/E, revenue and dividend
Industrials · United States · ISIN US68218J1034
OmniAb, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 18.67 m USD |
| Operating income | -68.97 m USD |
| EBIT | -68.95 m USD |
| Net income | -64.78 m USD |
| Diluted EPS – continuing operations | -0.57 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
More stocks
- HORIZON FIXTURE GROUP CO LTD (6957.TW)
- MOVADO GROUP INC (MOV)
- Talamore Mining Corp. (TALA.TO)
- Toyo Engineering Corp (6330.T)
- Shanghai Orient-Chip Technology Co. Ltd. A (688061.SS)
- Shanghai Laiyifen Co Ltd (603777.SS)
- Henan Senyuan Electric Co Ltd (002358.SZ)
- Zhejiang Cayi Vacuum Container Co. Ltd. (301004.SZ)
- Da-Cin Construction Co Ltd (2535.TW)
- New Huadu Supercenter Co Ltd (002264.SZ)
- Arbutus Biopharma Corp (ABUS)
- Shenzhen SDG Service Co. Ltd. (300917.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.